Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs PRLB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRLB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

PRLB Overall Winner 6-Pillar Tally: VIVS 0 – 6 PRLB Matrix Metrics: VIVS 0 – 10 PRLB

As of Nov 19, 2026, Proto Labs, Inc. (PRLB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas PRLB carries 62.1/100 (BUY) at $62.89 (25.0x Forward P/E, 8.1% operating margin).

  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile PRLB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs PRLB
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 5.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
PRLB NYSE Head-to-Head Winner
Proto Labs, Inc.
Fabricated Structural Metal Products
$62.89
-1.57% 1D
Market Cap $1.5B
TTM Revenue $579M
Forward P/E 25.0x
Beta / 30D Vol 1.85β · 75% Vol
Unified Composite Score
62.1 / 100 BUY
Tech 78.0 Fund 69.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.7%), weak momentum, RSI 31
RSI-14: 30.5 · SMA20: $71.45 · SMA50: $82.62

6-Pillar Scorecard Institutional Category Breakdown (VIVS 0 – 6 PRLB)

Columns: Metric · VIVS · PRLB
1. Valuation Multiples PRLB
Forward P/E N/M 25.0x
Trailing P/E N/M 43.8x
PEG Ratio N/M 0.86x
EV / Revenue 9.6x 2.4x
2. Growth & Scale PRLB
Revenue Growth (YoY) -51.4% +14.0%
Earnings Growth (YoY) +0.0% +60.0%
TTM Revenue (USD) $112,000 $579M
Market Cap $2.4M $1.5B
3. Profitability & Quality PRLB
Gross Margin N/A 45.2%
Operating Margin -10117.0% 8.1%
Net Profit Margin 0.0% 6.0%
Return on Equity (ROE) -343.1% 5.1%
4. Balance Sheet & Cash Flow PRLB
Cash Generation (TTM) -$11M EBITDA $49M
Cash Flow Margin N/A 8.4%
Net Cash / Leverage $1.4M Net Cash $130M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRLB
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 54.0% (9th %ile)
Put/Call OI Skew N/A 0.61x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PRLB
OpEx & R&D Intensity N/A 37.1% of Rev ($215M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Metal Fabrication Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (0) vs PRLB (10)
Institutional Metric VIVS PRLB Criterion Row Edge
Market Capitalization
Scale
$2.4M $1.5B Larger Scale PRLB
Trailing P/E Ratio
Valuation
N/M 43.8x Lower Multiple PRLB
Forward P/E Ratio
Valuation
N/M 25.0x Lower Multiple PRLB
Revenue Growth (YoY)
Growth
-51.4% +14.0% Higher Growth PRLB
Operating Margin (TTM)
Profitability
-10117.0% 8.1% Higher Margin PRLB
Net Profit Margin
Profitability
0.0% 6.0% Higher Margin PRLB
Return on Equity (ROE)
Capital Efficiency
-343.1% 5.1% Higher ROE PRLB
52-Week Range Position
Momentum
5% ($0–$3) 31% ($46–$100) Stronger Trend PRLB
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 1.85β · 75% Vol Lower Realized Risk PRLB
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 62.1 / 100 (BUY) Higher Composite PRLB
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $579M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 45.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev 0.86x PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) $49M ($130M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +94.57 pp
VIVS: +64.69% · PRLB: -29.88%
3M Horizon VIVS +22.92 pp
VIVS: +1.92% · PRLB: -21.0%
6M Horizon PRLB +68.41 pp
VIVS: -78.25% · PRLB: -9.84%
1Y Horizon PRLB +120.34 pp
VIVS: -86.99% · PRLB: +33.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VIVS Revenue PRLB Revenue VIVS Op. Margin PRLB Op. Margin Margin Leader
FY2019 $0M $460M -882.4% 17.4% PRLB
FY2020 $0M $430M -977.9% 13.8% PRLB
FY2021 N/A $490M N/A 8.3% PRLB
FY2022 $0M $490M -765.3% -20.1% PRLB
FY2023 $0M $500M -4792.2% 5.6% PRLB
FY2024 $0M $500M -13840.4% 4.0% PRLB
FY2025 $0M $530M -8761.1% 4.7% PRLB
FY2026 $0M N/A -8768.7% N/A VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRLB CONSOLIDATION
106d in phase · OBV DISTRIBUTION
Current IV 54.0%
IV Percentile 9th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PRLB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRLB Moat Profile Cyclical / Execution-Driven Positioning
Metal Fabrication Operator
Competes within the Metal Fabrication value chain with $1.5B market capitalization and 8.1% operating margin.
OpEx & R&D Reinvestment 37.1% of Rev ($215M)
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs PRLB Key Questions & Quantitative Answers

As of Nov 19, 2026, Proto Labs, Inc. (PRLB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas PRLB carries 62.1/100 (BUY) at $62.89 (25.0x Forward P/E, 8.1% operating margin). Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile PRLB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRLB leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with PRLB at +14.0% YoY revenue growth and +60.0% YoY earnings growth on $579M TTM revenue (45.2% gross margin, 8.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while PRLB shifted +15.2%. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 37.1% of Rev ($215M) (0 disclosures) for PRLB.

PRLB screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas PRLB trades at 25.0x Forward P/E, 43.8x Trailing P/E, 0.86x PEG, and 2.4x EV/Revenue (8.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus PRLB (5.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, PRLB carries 54.0% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.85β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.